#BEGIN_DRUGCARD DB08872

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Gabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1.

# Biotransformation:
Gabapentin enacarbil does not interact with any of the major cytochrome P450 
enzymes.

# Brand_Mixtures:
Not Available

# Brand_Names:
HORIZANT

# CAS_Registry_Number:
478296-72-9

# ChEBI_ID:
68840

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-02 15:20:52 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Gabapentin enacarbil is marketed under the name Horizant®. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

# Dosage_Forms:
Tablet, extended release	Oral
Tablet, extended release	Oral

# Drug_Category:
Anticonvulsants

# Drug_Interactions:
Azelastine	Avoid combination due to increased CNS depression.
Ethanol	Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression.

# Drug_Reference:
15146029	Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Solubility of 0.5 mg/mL in water

# Food_Interactions:
No food effects.

# GenBank_ID:
Not Available

# Generic_Name:
gabapentin enacarbil

# HET_ID:
Not Available

# Half_Life:
The elimination half-life of gabapentin is 5.1 to 6.0 hours.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D09539

# LIMS_Drug_ID:
8882

# Mechanism_Of_Action:
Although the exact mechanism of action of gabapentin in RLS and PHN is unknown, it is presumed to involve the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors.

# Melting_Point:
Melting onset of about 64°C.

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Since gabapentin enacarbil is a prodrug of gabapentin, it's physiological effects are the same as gabapentin. Concerning PHN, gabapentin prevents allodynia and hyperalgesia.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB08872

# Protein_Binding:
Gabapentin plasma protein binding is less than 3%.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/horizant-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Most common adverse reactions are headache, dizziness, and somnolence.

# Update_Date:
2013-05-03 13:44:59 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Gabapentin_enacarbil

# pKa_Isoelectric_Point:
pKa 5.0

#END_DRUGCARD DB08872
